CDK4/6-话题@MedSci

#CDK4/6#

47篇内容 | 1991人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1490722, encodeId=4b011490e2263, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, objectType=article, longId=736714, objectId=1cd4e36714ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cd4e36714ec, replyNumber=0, likeNumber=88, createdTime=2022-08-25, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cd4e36714ec, moduleTitle=HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cd4e36714ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490721, encodeId=8ed91490e2176, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6i不良反应管理手册来了！这篇总结的很全哦~, objectType=article, longId=733755, objectId=afe2e3375555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe2e3375555, replyNumber=0, likeNumber=84, createdTime=2022-07-30, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe2e3375555, moduleTitle=CDK4/6i不良反应管理手册来了！这篇总结的很全哦~, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe2e3375555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490720, encodeId=fbf01490e204e, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, objectType=article, longId=730361, objectId=69abe303613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69abe303613d, replyNumber=0, likeNumber=84, createdTime=2022-06-25, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69abe303613d, moduleTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69abe303613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490718, encodeId=c6f71490e1852, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, objectType=article, longId=729096, objectId=317ae2909688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317ae2909688, replyNumber=0, likeNumber=86, createdTime=2022-06-12, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317ae2909688, moduleTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317ae2909688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490719, encodeId=38ee1490e195e, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , objectType=article, longId=729095, objectId=d5c5e2909563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5c5e2909563, replyNumber=0, likeNumber=80, createdTime=2022-06-12, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5c5e2909563, moduleTitle=ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5c5e2909563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490717, encodeId=0d331490e17f8, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, objectType=article, longId=299159, objectId=5c4f2991594a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f2991594a, replyNumber=0, likeNumber=97, createdTime=2022-02-20, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f2991594a, moduleTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4f2991594a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490716, encodeId=0aa51490e16f3, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, objectType=article, longId=219389, objectId=f5d0219389bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d0219389bc, replyNumber=0, likeNumber=87, createdTime=2021-10-29, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d0219389bc, moduleTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d0219389bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490713, encodeId=94da1490e1301, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=118, createdTime=2021-06-29, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490715, encodeId=4fbb1490e15c4, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性, objectType=article, longId=211179, objectId=0aac2111e9ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0aac2111e9ad, replyNumber=0, likeNumber=96, createdTime=2021-05-13, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0aac2111e9ad, moduleTitle=2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0aac2111e9ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490712, encodeId=a87b1490e1298, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, objectType=article, longId=211171, objectId=30eb2111e1ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30eb2111e1ef, replyNumber=0, likeNumber=86, createdTime=2021-05-13, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30eb2111e1ef, moduleTitle=JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30eb2111e1ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490714, encodeId=22fb1490e1452, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者, objectType=article, longId=210931, objectId=06062109315d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06062109315d, replyNumber=0, likeNumber=64, createdTime=2021-05-09, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06062109315d, moduleTitle=2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06062109315d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490711, encodeId=83fe1490e112b, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌, objectType=article, longId=206821, objectId=c8452068210e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8452068210e, replyNumber=0, likeNumber=76, createdTime=2021-02-07, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8452068210e, moduleTitle=科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8452068210e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490710, encodeId=a7e31490e109e, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, objectType=article, longId=200588, objectId=285f20058863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=285f20058863, replyNumber=0, likeNumber=83, createdTime=2020-09-13, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285f20058863, moduleTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=285f20058863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490709, encodeId=d3071490e09a1, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗 , objectType=article, longId=195525, objectId=b61e195525f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61e195525f3, replyNumber=0, likeNumber=68, createdTime=2020-06-11, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61e195525f3, moduleTitle=Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61e195525f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490708, encodeId=b55e1490e083c, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, objectType=article, longId=192539, objectId=63c019253993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63c019253993, replyNumber=0, likeNumber=74, createdTime=2020-04-21, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63c019253993, moduleTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63c019253993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490707, encodeId=a5a91490e07e3, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, objectType=article, longId=186505, objectId=22ce186505e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ce186505e0, replyNumber=0, likeNumber=125, createdTime=2020-01-20, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ce186505e0, moduleTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ce186505e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490706, encodeId=b0f31490e064b, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, objectType=article, longId=184839, objectId=a8c018483912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c018483912, replyNumber=0, likeNumber=93, createdTime=2019-12-18, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c018483912, moduleTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c018483912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490705, encodeId=c8fe1490e058b, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂前途，乳腺癌免疫疗法值得期待, objectType=article, longId=184341, objectId=14291843415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14291843415e, replyNumber=0, likeNumber=91, createdTime=2019-12-08, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14291843415e, moduleTitle=CDK4/6抑制剂前途，乳腺癌免疫疗法值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14291843415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490704, encodeId=a7131490e04f4, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活, objectType=article, longId=184135, objectId=48f018413537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f018413537, replyNumber=0, likeNumber=80, createdTime=2019-12-05, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f018413537, moduleTitle=CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48f018413537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1490703, encodeId=e6201490e0391, content=<a href='/topic/show?id=2765440372' target=_blank style='color:#2F92EE;'>#CDK4/6#</a>, objectTitle=氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式, objectType=article, longId=180695, objectId=da1a180695a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da1a180695a6, replyNumber=0, likeNumber=82, createdTime=2019-10-10, rootId=0, userName=zhangj7111, userId=c7068807080, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da1a180695a6, moduleTitle=氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da1a180695a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK4/6

2020-05-29

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

HR+HER2-晚期乳腺癌CDK4/6i失败后治疗模式新探索

2022-08-25

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6i不良反应管理手册来了！这篇总结的很全哦~

2022-07-30

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌

2022-06-25

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！

2022-06-12

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

ASCO 2022 | PALOMA-2研究最终数据出炉：全球首款CDK4/6抑制剂哌柏西利再受挫！

2022-06-12

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤

2022-02-20

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析

2021-10-29

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2021-06-29

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

2021BOC/BOA：殷咏梅教授解读CDK4/6抑制剂阿贝西利中国临床实践数据，以期提高可及性

2021-05-13

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

JNCCN：乳腺癌患者CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗的疗效：多中心临床经验

2021-05-13

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

2021BOC/BOA：江泽飞教授解读CDK4/6抑制剂阿贝西利中国数据，期待惠及更多乳腺癌患者

2021-05-09

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

科学致胜，共克癌症 ——全球CDK4/6抑制剂持续响应“世界癌症日” 助力中国患者对抗晚期乳腺癌

2021-02-07

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤

2020-09-13

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗

2020-06-11

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果

2020-04-21

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌

2020-01-20

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功

2019-12-18

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂前途，乳腺癌免疫疗法值得期待

2019-12-08

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活

2019-12-05

zhangj7111 (审核中...)

前往app查看评论内容

#CDK4/6#

氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式

2019-10-10

科室
- - 订阅+
  - 更多科室
工具
服务